Insights
Find the latest updates, news and insights from across BAP Pharma’s expert teams.
July 20, 2026
For years, Rare Disease Access has been defined by three critical questions: Does a treatment exist? Is it approved? Will it be...
July 20, 2026
Across the life sciences industry, there is growing pressure to accelerate the path from development to patient access. Faster IND approvals, streamlined...
May 6, 2026
The Ehlers-Danlos Society – Why are people with EDS and HSD receiving such late access to innovative therapies? What is Ehlers-Danlos syndrome...
March 12, 2026
Managed Access Programs are a key pillar of the drug development lifecycle, yet they remain widely misunderstood – both by the people...
February 13, 2026
How we help Biotechs save lives sooner Patients with rare diseases face all kinds of challenges in their lives, including accessing the...
July 21, 2025
How It Started One of our key focuses at BAP Pharma is to actively engage with patient advocacy groups (PAGs), particularly in...
May 20, 2025
Early Access Programs (EAPs) offer a critical pathway for patients with serious or life-threatening conditions to access potentially life-saving treatments before they...
Revolutionizing Clinical Trial Supply: How BAP Pharma’s Agile Approach Redefines Comparator Sourcing
May 19, 2025
Clinical trials are the backbone of medical innovation, but they require precision, efficiency, and adaptability to succeed. Traditional comparator sourcing and clinical...
March 6, 2023
BAP Pharma are excited and proud to announce that we have achieved a Gold Rating in the EcoVadis Sustainability ratings – placing...